Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH)

Contraception

Volumn 62, Issue 5, 2000, Pages 259-269

  Balogh, A ^a   Kauf, E ^a   Vollanth, R ^a   Graser G ^b   Klinger, G ^a   Oettel, M ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Growth hormone (hGH); Insulin like growth factor binding protein 3 (IGFBP 3); Insulin like growth factor I (IGF I); Oral contraceptive steroids

Indexed keywords

CONTRACEPTIVE AGENT; DIENOGEST PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AGE; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BONE; CONNECTIVE TISSUE; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONAL CONTRACEPTION; HUMAN; NORMAL HUMAN; ORAL CONTRACEPTION; PILL;

CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LEVONORGESTREL; LINEAR MODELS; NANDROLONE; TIME FACTORS;

EID: 0034496534     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(00)00176-1     Document Type: Article

References (35)

1. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay
2. Pathophysiological and clinical aspects of the insulin-like growth factors
3. AP-1-like motif as a key to understanding the insulin-like growth factor I (IGF-I) gene regulation
4. Effect of natural menopause on serum levels of IGF I and IGF binding proteins: Relationship with bone mineral density and lipid metabolism in perimenopausal women
5. Insulin-like growth factor expression in breast-cancer epithelium and stroma
6. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
7. Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women
8. Effect of short-term medroxyprogesterone acetate on left ventricular mass: Role of insuline-like growth factor-1
9. Insulin-like growth factorl (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: A possible bimodal effect depending on basal IGF-I values
10. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding protein 1 and 3: A cross-over study
11. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels
12. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-a clinical research center study
13. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women
14. Hormonal treatments modulate pusatile plasma growth hormone, gonadotrophin and osteocalcin levels in postmenopausal women
15. Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy
16. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and binding protein in postmenopausal women
17. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report
18. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages
19. Effects of aging and dietary restriction on tissue protein synthesis: Relationship to plasma insulin-like growth factor
20. The IGF system in metabolism regulation
21. Altered growth hormone secretion during oral contraception
22. Effect of oral contraceptives on adrenocorticotropin and growth hormone secretion following CRH and GHRH administration
23. Effect of oestrogen status on serum levels of growth hormone-binding protein and insulin-like growth factor-I in non-pregnant and pregnant women
24. Growth hormone and somatomedin C during postmenopausal replacement therapy with oestrogen alone and in combination with an antioestrogen
25. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women
26. Can oral contraceptive steroids influence the elimination of nifedipine and its primary metabolite in humans?
27. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle
28. The response of the growth hormone and insuline-like growth factor I axis to medical castration in women with polycystic ovarian syndrome
29. Insulin-like growth factors I and II. Peptide, Messenger ribonucleic acid and gene structures, serum, and tissue concentrations
30. Modulatory role of estrogens and progestins on growth hormone episodic release in women with hypothalamic amenorrhea
31. Effects of hormone replacement therapy on growth hormone secretion pattern in correlation to somatometric parameters in healthy postmenopausal women
32. The ratio between serum levels of insulin-like growth factor (IGF-I) and the IGF binding proteins (IFGBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
33. Insulin-like growth factor binding protein 3 is decreased in early stage operable pre-menopausal breast cancer